FARAPULSE™
Pulsed Field Ablation System

Boston Scientific
Advancing science for life™

FARAPULSE transforms AFib treatment by delivering favorable outcomes, procedure efficiencies, and economic benefits.

CLINICAL CHALLENGE

Atrial fibrillation (AFib), the most common arrhythmia, increases the risk of stroke, heart failure, and death.[1] With an estimated U.S. prevalence of 10.5 million[2] and rising, hospitals face capacity constraints, leading to delays between diagnosis and treatment.

Traditional thermal ablation is associated with variable procedure times and rare yet serious adverse events, such as esophageal fistula, pulmonary vein stenosis, and permanent phrenic nerve injury.[3]

Pulsed field ablation (PFA) is a novel approach that uses nonthermal electric fields to selectively ablate heart tissue. Because the catheter design, waveform, and dosing protocol impact outcomes, each PFA system must be evaluated independently.

THE SOLUTION

With proven safety, efficacy, and more predictable case times, the purpose-built FARAPULSE PFA System may increase patient throughput and bring economic benefits to health systems.

With a variable tip that uses 'flower' and 'basket' form factors, the FARAWAVE™ PFA Catheter delivers ostial and antral lesions and conforms to different patient anatomies.

As the first focal PFA catheter, FARAPOINT™ extends the FARAPULSE™ ecosystem with point-by-point, non-thermal ablation capability, including adjunctive CTI ablation alongside FARAWAVE.

Now with full integration with the OPAL HDx™ Mapping System, FARAPULSE offers a single-catheter map-and-ablate workflow, leading to greater efficiencies and case cost savings.

Strong Safety Profile

- <1% major adverse event from the largest real-world FARAPULSE Registry MANFIEST-17K[4]

Robust Clinical Evidence

- 270+ clinical publications
- Higher durability of pulmonary vein isolation (PVI) than thermal[5]
- Met primary efficacy and safety endpoints in ADVENT, the largest PFA clinical trial to date and only randomized controlled trial comparing PFA to cryoablation and radiofrequency ablation[6]

Efficient and Consistent Workflow

- Significantly shorter and less variable procedure times[6,7]
- Improved patient throughput by enabling more cases each case day
- Option for non-intubated anesthesia workflow*
- Supports a same-day discharge operating model

↓ 42%
average reduction in ablation time[6]

FARAPULSE™
Pulsed Field Ablation System

Boston Scientific
Advancing science for life™

REAL WORLD DATA
Reported skin-to-skin procedure times



Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

IMPROVING PATIENT HEALTH

FARAPULSE is purpose built for cardiac PFA and to optimize ablation procedures for the growing AFib patient population.

500,000+
patients treated globally

10+ Years
optimizing and validating catheter design, waveform, and workflow

References

1. "Why is Afib a Problem?" StopAfib.org. July 5, 2021. https://www.stopafib.org/learn-about-afib/why-is-afib-a-problem/.
2. Noubiap, J, Tang, J, Teraoka, J. et al. Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities. JACC. null2024, 0 (0). https://doi.org/10.1016/j.jacc.2024.07.014
3. Benali K, Khairy P, Hammache N, et al. Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation. J Am Coll Cardiol. 2023 May, 81 (21) 2089–2099.https://doi.org/10.1016/j.jacc.2023.03.418
4. Ekanem E, Reddy VY, et al. Multi-National Survey on the Safety of the post-approval clinical use of Pulsed Field Ablation in 17,000+ patients (MANIFEST 17K). Presented at AHA 2023 on 11/12/23.
5. Della Rocca DG, Marcon L, Magnocavallo M, et al. Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: A propensity score-matched comparison. Europace. 2023;26(1):euae016.
6. Reddy VY, Gerstenfeld EP, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. New England Journal of Medicine. 2023. August 2023.
7. Schmidt B, Bordignon S, Neven K, et al. European real-world outcomes with Pulsed field ablation in patients with symptomatic atrial fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023. June 28.
8. Hoffmann E, Straube F, Wegscheider K, Kuniss M, Andresen D, Wu LQ et al. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace 2019;21:1313–24.
9. De Potter T, et al. Safety and long-term effectiveness of paroxysmal atrial fibrillation ablation with a contact force-sensing catheter: real-world experience from a prospective, multicentre observational cohort registry. EP Europace. Nov 2018.
10. Honarbakhsh S, Martin C, et al. Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience. EP Europace. Nov 2023.
11. Badertscher P, Weidlich S, et al. Pulsed-field ablation versus single-catheter high-power short-duration radiofrequency ablation for atrial fibrillation. HRS journal. 2023 May 9. Represents the IQR, with the median at 83 min.
12. Schmidt B, Bordignon S, Neven K, et al. European real-world outcomes with Pulsed field ablation in patients with symptomatic atrial fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023. June 28.
13. Schmidt B, Bordignon S, Tohoku S, et al. 5S Study: Safe and Simple Single Shot Pulmonary Vein Isolation with Pulsed Field Ablation Using Sedation. CIRCULATION. 2022. May 26.
14. Tilz RR, Vogler J, Kirstein B, et al. Pulsed Field Ablation-Based Pulmonary Vein Isolation using a Simplified Single-Access Single-Catheter Approach. Circ J. 2023 Aug 3.

* Dependent on facility-specific protocols and physician assessment of each patient.

FARAPULSE™ Pulsed Field Ablation System Indications, Safety and Warnings
OPAL HDx™ Mapping System Indications, Safety and Warnings

© 2026 Boston Scientific Corporationor its affiliates. All rights reserved.
www.bostonscientific.com/administrators
CORP-2499606-AA-MAY 2026